April 11, 2019
Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases
Ophtotech entered into an exclusive global licenseagreement for rights to developand commercialize novel adeno-associated virus (AAV) gene therapyproduct candidates for the treatment of Best vitelliform maculardystrophy.